Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Carna BiosciencesTSE:4572 +2.27%38 Days Payable is 0.66 as of Dec. 2025, which is 83% below its 10-year median of 3.94. GuruFocus rates TSE:4572 with a GF Score™ of 38/100 and a GF Value™ of 円184.92 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 703 Biotechnology companies, Carna Biosciences ranks worse than 99.15% on this metric.
The historical rank and industry rank for Carna Biosciences's Days Payable or its related term are showing as below:
TSE:4572'
s Days Payable Range Over the Past 10 Years
Min: 2.37 Med: 3.94 Max: 63.48
Current: 3.93
During the past 13 years, Carna Biosciences's highest Days Payable was 63.48. The lowest was 2.37. And the median was 3.94.
TSE:4572's Days Payable is ranked worse than 99.15% of 703
companies
in the Biotechnology industry
Industry Median: 112.61
vs TSE:4572: 3.93
Carna Biosciences's Days Payable
increased
from Dec. 2024 (0.00) to Dec. 2025 (0.66).
It may suggest that Carna Biosciencesdelayed paying its suppliers.
The historical data trend for Carna Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4572 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Carna Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carna Biosciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Carna Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Carna Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Carna Biosciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carna Biosciences (TSE:4572) has a Days Payable of 0.66 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Carna Biosciences and its competitors. This is 83% below median its historical median of 3.94. Over the past decade, Carna Biosciences' Days Payable has ranged from 2.37 to 63.48. According to the industry distribution chart, Carna Biosciences ranks #697 out of 703 companies in the Biotechnology industry, placing it in the top 99.1%.
Is Carna Biosciences' Days Payable too high?
Carna Biosciences' current Days Payable of 0.66 is 83% below median its 10-year median of 3.94. Over the past 10 years, this metric has ranged from a low of 2.37 to a high of 63.48. The Biotechnology industry median Days Payable is 112.61. Carna Biosciences' value of 0.66 is 99.4% below this industry median. Based on the distribution chart, Carna Biosciences ranks #697 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Carna Biosciences has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Carna Biosciences ranks #697 out of 703 companies for Days Payable. This places Carna Biosciences in the lower half of its industry. The industry median Days Payable is 112.61. Carna Biosciences' value of 0.66 is 99.4% below this benchmark. Historically, Carna Biosciences' own Days Payable has ranged from 2.37 to 63.48 over the past decade. While the company's 10-year median is 3.94 vs. the industry median of 112.61, Carna Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.61, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carna Biosciences's current Days Payable of 0.66 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Carna Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 112.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carna Biosciences's current Days Payable is 0.66, which is 83% below median its own 10-year median of 3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円184.92, compared to a current price of 円316.00 — trading 70.9% above its estimated fair value. The current Days Payable is 0.66, which is 83% below median its 10-year median of 3.94 and 99.4% below the Biotechnology industry median of 112.61. Carna Biosciences' overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Days Payable is 0.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carna Biosciences (TSE:4572) Overvalued in 2026?
Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued.
The current stock price of 円316.00 is trading 70.9% above its estimated GF Value™ of 円184.92.
GuruFocus considers Carna Biosciences to be Significantly Overvalued.
Key valuation signals for TSE:4572:
Days Payable: 0.66 (83% below median its 10-year median of 3.94)
GF Value™: 円184.92 vs. price of 円316.00 (70.9% above fair value)
Industry Position: 99.4% below the Biotechnology median (#697 of 703)
No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
38GF Score
Get the complete analysis for TSE:4572
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4572 has been successfully added to your 
